# US 2019/0292230 A1 · Selective recovery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0292230 A1
- Document ID: US20190292230A1
- Status: Published application
- Kind: A1
- Application number: 16/379,641
- Filed: 2019-04-09
- Published: 2019-09-26
- Earliest claimed: 2013-09-13
- Assignees: California Institute of Technology
- Applicants: California Institute of Technology
- Inventors: Benjamin E. Deverman; Paul H. Patterson; Viviana Gradinaru
- Web page: https://patentgrep.com/patent/US20190292230A1

## CPC

- C07K 14/005: from viruses
- A61K 38/1709: {from mammals}
- A61K 38/2093: {Leukaemia inhibitory factor [LIF]}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 38/4813: {Exopeptidases (3.4.11. to 3.4.19)}
- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K 7/06: having 5 to 11 amino acids
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/1068: {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- C12N 2810/6027: ssDNA viruses
- C12Y 304/14009: Tripeptidyl-peptidase I (3.4.14.9)
- C12Y 305/01015: Aspartoacylase (3.5.1.15)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.

## Claims

### Claim 1

A method of generating an AAV with a desired tropism, the method comprising:
providing a population of rAAV genomes, wherein each of the rAAV genomes comprises:
an AAV capsid gene, and
two or more recombinase recognition sequences for a recombinase, wherein the recognition sequences are configured to allow generation of a recombinase-dependent change that is detectable;
transfecting a target cell expressing the recombinase with the population of rAAV genomes, whereby the recombinase induces a recombination event to generate a recombinase-dependent change in at least one of the rAAV genomes of the population, and wherein the recombinase-dependent change comprises an inversion of the sequences that are flanked by the recognition sequences;
detecting at least one recombinase-dependent change; and
identifying an rAAV genome generated by the at least one recombinase-dependent change, wherein said identified rAAV genome comprises the inversion, and wherein said identified rAAV genome encodes an AAV capsid with the desired tropism.

### Claim 2 (depends on 1)

The method of claim 1, wherein the target cell is present in a tissue, an organ, an organism, or a combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the capsid genes of the population of rAAV genomes encode mutant capsid proteins.

### Claim 4 (depends on 1)

The method of claim 1, wherein at least two of the two or more recombinase recognition sequences are in a head-to-head orientation.

### Claim 5 (depends on 1)

The method of claim 1, wherein the recombinase is a Cre recombinase.

### Claim 6 (depends on 5)

The method of claim 5, wherein the at least two of the two or more recombinase recognition sequences are two loxP sites or variants of loxP sites.

### Claim 7 (depends on 1)

The method of claim 1, wherein the target cell is a neuronal cell, a neural stem cell, an astrocytes, a tumor cell, a hematopoetic stem cell, an insulin producing beta cell, a lung epithelium, a skeletal cell, or a cardiac muscle cell.

### Claim 8 (depends on 1)

The method of claim 1, wherein the target cell is located in a brain or spinal cord.

### Claim 9 (depends on 1)

The method of claim 1, further comprising recovering the rAAV that is identified to have a capsid with the desired tropism.

### Claim 10

A method of generating an AAV with a desired tropism, the method comprising:
providing a population of rAAV genomes, wherein each of the rAAV genomes comprises:
an AAV capsid gene, and
one or more recognition sequences for a recombinase, wherein the one or more recognition sequences are configured to allow generation of a recombinase-dependent change that is detectable;
transfecting a target cell expressing the recombinase with the population of rAAV genomes, wherein the target cell is in a transgenic mammal comprising transgenic expression of the recombinase, and whereby the recombinase induces a recombination event to generate a recombinase-dependent change in at least one of the rAAV genomes of the population;
detecting at least one recombinase-dependent change; and
identifying an rAAV genome generated by the at least one recombinase-dependent change wherein said identified rAAV genome encodes an AAV capsid with the desired tropism.

### Claim 11 (depends on 10)

The method of claim 10, wherein the target cell is present in a tissue, an organ, an organism, or a combination thereof.

### Claim 12 (depends on 10)

The method of claim 10, wherein the capsid genes of the population of rAAV genomes encode mutant capsid proteins.

### Claim 13 (depends on 10)

The method of claim 10, wherein the recombinase is Cre recombinase.

### Claim 14 (depends on 13)

The method of claim 13, wherein the one or more recombinase recognition sequences comprise two or more recombinase-recognition sequences.

### Claim 15 (depends on 13)

The method of claim 13, wherein the recombinase-dependent change comprises an inversion of the sequences that are flanked by the recombinase-recognition sequences; and wherein the method comprises identifying the rAAV genomes that comprise the inversion.

### Claim 16 (depends on 14)

The method of claim 14, wherein at least two of the two or more recombinase-recombinase recognition sequences are in a head-to-head orientation.

### Claim 17 (depends on 10)

The method of claim 10, wherein the recombinase is a Cre recombinase.

### Claim 18 (depends on 17)

The method of claim 17, wherein the at least two of the two or more recombinase recognition sequences are two loxP sites or variants of loxP sites.

### Claim 19 (depends on 10)

The method of claim 10, wherein the target cell is a neuronal cell, a neural stem cell, an astrocytes, a tumor cell, a hematopoetic stem cell, an insulin producing beta cell, a lung epithelium, a skeletal cell, or a cardiac muscle cell.

### Claim 20 (depends on 10)

The method of claim 10, wherein the target cell is located in a brain or spinal cord.

### Claim 21 (depends on 10)

The method of claim 10, further comprising recovering the rAAV that is identified to have a capsid with the desired tropism.

### Claim 22 (depends on 10)

The method of claim 10, wherein the mammal is a mouse.
